Chemical Research in Chinese Universities ›› 2022, Vol. 38 ›› Issue (4): 886-893.doi: 10.1007/s40242-022-2119-5

• Reviews • Previous Articles     Next Articles

Recent Progress in Mass Spectrometry-based Metabolomics for Colorectal Cancer

XIAO Chulei, CHI Quan, WANG Xian   

  1. Key Laboratory of Analytical Chemistry of the State Ethnic Affairs Commission, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan 430074, P. R. China
  • Received:2022-03-30 Revised:2022-04-30 Online:2022-08-01 Published:2022-07-01
  • Contact: WANG Xian E-mail:xwang27@mail.scuec.edu.cn
  • Supported by:
    This work was supported by the National Natural Science Foundation of China(No.21675176), the Key Research and Development Program of Hubei Province, China(No.2020BCB032) and the Fundamental Research Funds for the Central Universities, South-Central Minzu University, China(No.CZP21002).

Abstract: Metabolomics, one of the latest omics technologies, is employed to reveal overall metabolic trajectories, identify disease causative mechanisms and provide information for preventive diagnosis and drug targeting. Cancer is a disease known to alter cellular metabolism and so metabolomics can play an important role in the early diagnosis of cancer and in the evaluation of medical interventions and treatments for cancer. Many metabolomics studies rely on high-sensitive and high-throughput mass spectrometry platforms. In recent years, various mass spectrometry(MS) methodologies have been developed and enriched the scope of metabolite detection, contributing to disease studies, such as diabetes, cancer, and depression. Colorectal cancer is the third most diagnosed cancer worldwide and its incidence ranked third in China. This review focuses on the mass spectrometry technologies in metabolomics and summarizes the progress of metabolomics research in colorectal cancer.

Key words: Metabolomics, Mass spectrometry, Colorectal cancer, Biomarker